Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

Advancing chimeric antigen receptor (CAR)-engineered adoptive T cells for the treatment of solid cancers is a major focus in the field of immunotherapy, given impressive recent clinical responses in hematological malignancies. Prostate cancer may be amenable to T cell-based immunotherapy since sever...

Full description

Bibliographic Details
Main Authors: Saul J. Priceman, Ethan A. Gerdts, Dileshni Tilakawardane, Kelly T. Kennewick, John P. Murad, Anthony K. Park, Brook Jeang, Yukiko Yamaguchi, Xin Yang, Ryan Urak, Lihong Weng, Wen-Chung Chang, Sarah Wright, Sumanta Pal, Robert E. Reiter, Anna M. Wu, Christine E. Brown, Stephen J. Forman
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
car
co-stimulatory domain
immunotherapy
prostate cancer
psca
chimeric antigen receptor
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1380764

Internet

http://dx.doi.org/10.1080/2162402X.2017.1380764

Similar Items